About Cytonics Corporation
In the U.S., over 30 million people are treated for back pain every year, and osteoarthritis (OA) affects nearly 27 million people. Back pain is the number one cause of missed work and the number one healthcare expense in our country. Joint pain and OA account for millions of doctor office visits each year, and are rapidly rising as the average life expectancy increases. In all, musculoskeletal disease burdens our nation with human suffering, lost productivity, missed work, and excessive medical expenses. ​

Background
Business Summary
Cytonics is developing protein-based diagnostics and therapeutics for orthopedic pain. We have discovered a unique “bio-marker” that can assist physicians in improving patient outcomes by pinpointing the source of orthopedic pain. We are also developing a range of therapeutic products for the treatment of osteoarthritis, back, and joint pain. Cytonics has a 5,900sqft research lab located in Jupiter, FL with a team of 13 scientists, including 3 PhD’s, working to discover and develop products for the treatment of musculoskeletal disease.
Management Team
Ray Johnson, MBA, President
Gaetano Scuderi, M.D., Chief Medical Officer
Robert Bowser, Ph.D., Chief Scientific Officer
Lewis Hanna, Ph.D., VP Research & Development
Raymond Golish, M.D., Ph.D., VP Clinical Research

Capitalization
The company has received over $14M in funding, including $1.8M in grants from the National Institute of Health. The DePuy Synthes division of Johnson & Johnson purchased a 20% interest in Cytonics in 2011. Our corporate and securities counsel is Edwards Wildman Palmer LLP.

Intellectual Property
Cytonics has invested over $500K in patent development to protect our diagnostic and therapeutic technologies. Our products are protected by one or more of the following patents: U.S. Patent #7,709,215 and #8,338,572, as well as numerous US and international patents pending. Our patent counsel is Wilson Sonsini Goodrich and Rosati.